# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Yi Chen reiterates Icecure Medical (NASDAQ:ICCM) with a Buy and maintains $3 price target.
IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minima...
ICESECRET interim results, as previously announced, demonstrated ProSense® to be safe and effective in treating kidney tumors w...
HC Wainwright & Co. analyst Yi Chen reiterates Icecure Medical (NASDAQ:ICCM) with a Buy and maintains $3 price target.
HC Wainwright & Co. analyst Yi Chen reiterates Icecure Medical (NASDAQ:ICCM) with a Buy and maintains $3 price target.
Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is ...